Sarepta Therapeutic Gets Booed and 4 More Analysts Downgrades To Know
Stock upgrades and downgrades are a controversial part of Wall Street. Despite regulations, many banks and firms still have a positive bias toward current clients and companies desired as future clients. In addition, Wall Street analysts are straight-up biased to the buy side. The percentage of sell recommendations is normally below 15 percent!
Regardless, upgrades and downgrades move stocks in the short-term. They fall into our CHEAT SHEET framework category ‘C = Catalyst for a Stock?s Movement’. Here are catalysts you must know today:
Sarepta Therapeutic (NASDAQ:SRPT): Leerink Swann downgraded its rating on this company from Outperform to Market Perform and changed its price target to $419.00.
Spectra Energy Partners (NYSE:SEP): Citigroup downgraded its rating on this company from Buy to Neutral.
SunoCo Logistics Partners LP (NYSE:SXL): Citigroup downgraded its rating on this company from Buy to Neutral.
Chicago Bridge & Iron Company (NYSE:CBI): Macquarie downgraded its rating on this company from Neutral to Underperform.
C.H. Robinson Worldwide (NASDAQ:CHRW): JPMorgan Chase downgraded its rating on this company from Neutral to Underweight and changed its price target to $50.00.
Investing Insights: Is Dendreon Undervalued?